Literature DB >> 25319010

Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1-Dependent Trafficking of Integrins.

Polina Y Kozyulina1, Yuriy V Loskutov2, Varvara K Kozyreva2, Anuradha Rajulapati2, Ryan J Ice2, Brandon C Jones3, Elena N Pugacheva4.   

Abstract

UNLABELLED: The dissemination of tumor cells relies on efficient cell adhesion and migration, which in turn depends upon endocytic trafficking of integrins. In the current work, it was found that depletion of the prometastatic protein, NEDD9, in breast cancer cells results in a significant decrease in individual cell migration due to impaired trafficking of ligand-bound integrins. NEDD9 deficiency does not affect the expression or internalization of integrins but heightens caveolae-dependent trafficking of ligand-bound integrins to early endosomes. Increase in mobility of ligand-bound integrins is concomitant with an increase in tyrosine phosphorylation of caveolin-1 (CAV1) and volume of CAV1-vesicles. NEDD9 directly binds to CAV1 and colocalizes within CAV1 vesicles. In the absence of NEDD9, the trafficking of ligand-bound integrins from early to late endosomes is impaired, resulting in a significant decrease in degradation of ligand-integrin complexes and an increase in recycling of ligand-bound integrins from early endosomes back to the plasma membrane without ligand disengagement, thus leading to low adhesion and migration. Reexpression of NEDD9 or decrease in the amount of active, tyrosine 14 phosphorylated (Tyr14) CAV1 in NEDD9-depleted cells rescues the integrin trafficking deficiency and restores cellular adhesion and migration capacity. Collectively, these findings indicate that NEDD9 orchestrates trafficking of ligand-bound integrins through the attenuation of CAV1 activity. IMPLICATIONS: This study provides valuable new insight into the potential therapeutic benefit of NEDD9 depletion to reduce dissemination of tumor cells and discovers a new regulatory role of NEDD9 in promoting migration through modulation of CAV1-dependent trafficking of integrins. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25319010      PMCID: PMC4369181          DOI: 10.1158/1541-7786.MCR-14-0353

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces.

Authors:  J Wegener; C R Keese; I Giaever
Journal:  Exp Cell Res       Date:  2000-08-25       Impact factor: 3.905

2.  A novel model system for characterization of phagosomal maturation, acidification, and intracellular collagen degradation in fibroblasts.

Authors:  P D Arora; M F Manolson; G P Downey; J Sodek; C A McCulloch
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

3.  A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase.

Authors:  Haiming Cao; William E Courchesne; Cynthia Corley Mastick
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

4.  Adaptor protein-2 exhibits alpha 1 beta 1 or alpha 6 beta 1 integrin-dependent redistribution in rhabdomyosarcoma cells.

Authors:  Nikhat D Boyd; Bosco M C Chan; Nils O Petersen
Journal:  Biochemistry       Date:  2002-06-11       Impact factor: 3.162

Review 5.  Intracellular trafficking of raft/caveolae domains: insights from integrin signaling.

Authors:  Asier Echarri; Olivia Muriel; Miguel A Del Pozo
Journal:  Semin Cell Dev Biol       Date:  2007-08-19       Impact factor: 7.727

6.  NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.

Authors:  Sarah L McLaughlin; Ryan J Ice; Anuradha Rajulapati; Polina Y Kozyulina; Ryan H Livengood; Varvara K Kozyreva; Yuriy V Loskutov; Mark V Culp; Scott A Weed; Alexey V Ivanov; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2013-11-07       Impact factor: 5.852

7.  NEDD9 promotes oncogenic signaling in mammary tumor development.

Authors:  Eugene Izumchenko; Mahendra K Singh; Olga V Plotnikova; Nadezhda Tikhmyanova; Joy L Little; Ilya G Serebriiskii; Sachiko Seo; Mineo Kurokawa; Brian L Egleston; Andres Klein-Szanto; Elena N Pugacheva; Richard R Hardy; Marina Wolfson; Denise C Connolly; Erica A Golemis
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

8.  NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 3D cell migration.

Authors:  Jessie Zhong; Jaime B Baquiran; Navid Bonakdar; Justin Lees; Yu Wooi Ching; Elena Pugacheva; Ben Fabry; Geraldine M O'Neill
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

9.  Sorting of the FGF receptor 1 in a human glioma cell line.

Authors:  Regina Irschick; Tobias Trost; Georg Karp; Barbara Hausott; Maria Auer; Peter Claus; Lars Klimaschewski
Journal:  Histochem Cell Biol       Date:  2012-08-18       Impact factor: 4.304

10.  An ultrasensitive sorting mechanism for EGF receptor endocytosis.

Authors:  Hannah Schmidt-Glenewinkel; Ivayla Vacheva; Daniela Hoeller; Ivan Dikic; Roland Eils
Journal:  BMC Syst Biol       Date:  2008-04-07
View more
  7 in total

1.  Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide.

Authors:  Gokhan Baris Ozdener; Manish V Bais; Philip C Trackman
Journal:  Mol Oncol       Date:  2015-08-06       Impact factor: 6.603

2.  Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.

Authors:  Varvara K Kozyreva; Anna A Kiseleva; Ryan J Ice; Brandon C Jones; Yuriy V Loskutov; Fatimah Matalkah; Matthew B Smolkin; Kristina Marinak; Ryan H Livengood; Mohamad A Salkeni; Sijin Wen; Hannah W Hazard; Ginger P Layne; Callee M Walsh; Pamela S Cantrell; Greg W Kilby; Sricharan Mahavadi; Neal Shah; Elena N Pugacheva
Journal:  Mol Cancer Ther       Date:  2016-05-27       Impact factor: 6.261

Review 3.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

4.  Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.

Authors:  Brandon C Jones; Laura C Kelley; Yuriy V Loskutov; Kristina M Marinak; Varvara K Kozyreva; Matthew B Smolkin; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2017-02-24       Impact factor: 5.852

Review 5.  Vesicular trafficking-related proteins as the potential therapeutic target for breast cancer.

Authors:  Mohd Mughees; Himanshu Chugh; Saima Wajid
Journal:  Protoplasma       Date:  2019-12-11       Impact factor: 3.356

6.  Spatio-Temporal Gene Expression Profiling during In Vivo Early Ovarian Folliculogenesis: Integrated Transcriptomic Study and Molecular Signature of Early Follicular Growth.

Authors:  Agnes Bonnet; Bertrand Servin; Philippe Mulsant; Beatrice Mandon-Pepin
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

7.  Silencing NEDD9 by lentivirus-delivered shRNA inhibits the growth of BxPC-3 cells in vitro and in vivo.

Authors:  Tielong Wu; Yuanyuan Dai; Lili Xue; Yingyue Sheng; Yao Zhong; Yuzheng Xue
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.